Introduction
On the basis of the differential expression of protein chains constituting the heterodimer of the T-cell receptor (TCR), T cells can be divided into ab and cd T lymphocytes. Whereas the vast majority of circulating and peripheral T cells are ab lymphocytes and are involved in the adaptive immune response, cd T cells are predominantly confined to a few specific anatomical compartments such as the skin and mucosa and submucosa of the gastrointestinal tract, where they are believed to defend against pathogens at the epidermal or mucosal surfaces with a rapid proinflammatory response as part of the innate immune system. 1 cd T-cell lymphomas (GDTCLs) are aggressive haematological malignancies 2 that predominantly evolve in the spleen and liver (hepatosplenic type) or in the skin, with rapid progression and involvement of extracutaneous tissues (primary cutaneous GDTCL). [3] [4] [5] Primary cutaneous GDTCL is a cytotoxic cutaneous T-cell lymphoma (CTCL) defined by the expression of TCRcd in the absence of expression of TCRab, and often in the absence of T-cell maturation markers. 6, 7 Historically, GDTCLs were immunohistochemically characterised by the identification of the d-1 TCR chain in frozen tissue, 8 or, later, in formalin-fixed paraffin-embedded (FFPE) tissues by verification of the absence of the TCRb chain by the use of a monoclonal antibody (mAb) against TCRb and cytotoxic marker expression. 6 More recently, the presence of TCRc could also be immunohistochemically detected in FFPE tissues with mAb clone g3.20. 9, 10 However, the use of an anti-TCRc reagent for the detection of GDTCLs has not been without challenges. Atypical simultaneous expression of mutually exclusive TCR chains has been observed in lymphoma. TCRc positivity, for example, has been described in cases with TCRab expression [11] [12] [13] and monoclonal TCRb gene rearrangements. 14 In our study, we have validated the use of a mAb against TCRd in FFPE tissue of CTCL. Additional objectives were to assess the utility of TCRd labelling in FFPE tissue for diagnostic and prognostic purposes in GDTCLs, and within a spectrum of CTCLs/cutaneous lymphoproliferative disorders (CLPDs), to determine whether the pattern of expression might be distinct from recently reported promiscuous patterns of TCRc expression. Finally, we aimed to qualitatively characterise the presence of cd T cells in CTCL/CLPD in order to improve diagnostic/prognostic algorithms.
Materials and methods

T I S S U E S A M P L E S
The study was conducted with approval of the institutional review board of Memorial Sloan Kettering Cancer Center. All included patients were evaluated and treated at our institution. Cases were identified from a pathology database and a tissue archive search for cutaneous GDTCLs and other CTCLs/ CLPDs. A total of 144 skin biopsies with sufficient available archival material from 137 patients were identified. Clinical charts, anatomical, haematological and molecular pathology reports and histological and immunohistochemical material were reviewed.
The complete cohort of cases evaluated included 60 mycosis fungoides (MF) cases (44%), 15 primary cutaneous GDTCL cases (11%), 11 subcutaneous panniculitis-like T-cell lymphoma cases (SPTCL) (8%), five lymphomatoid papulosis (LyP) cases (4%), five primary cutaneous CD30
+ anaplastic large-cell lymphoma (ALCL) cases (4%), 14 unspecified CD30 + lymphoproliferative disorder (LPD) cases (10%), five CD8 + aggressive epidermotropic T-cell lymphoma (AETCL) cases (4%), three primary cutaneous peripheral T-cell lymphoma, not otherwise specified cases (2%), four natural killer/T-cell lymphoma cases (3%), three CD4 + small/medium pleomorphic T-cell lymphoproliferative disorder cases (2%), and one adult T-cell leukaemia/lymphoma case (<1%). Cases lacking unequivocal clinical certainty included five cases in which it was difficult to discern ALCL from transformed CD30 + MF (4%), three TCRc+ epitheliotropic lymphomas which have yet to reveal themselves as MF with a TCRc+ phenotype or GDTCL (2%), and three panniculitic partial TCRc+ lymphomas intermediate between GDTCL and SPTCL (<1%). Clinical data was collected, including lesion morphology and time from presentation to survival or last follow-up for both bona fide GDTCL cases and other cases with increased staining by TCRd immunohistochemistry.
H I S T O P A T H O L O G Y A N D I M M U N O H I S T O C H E M I S T R Y
Haematoxylin and eosin-stained sections were reviewed in order to confirm diagnosis, as per the 2016 revision to the World Health Organization classification of lymphoid neoplasms. 7 Archived immunohistochemically stained sections were reviewed for expression of T-cell markers, including CD3, CD4, CD7, CD8, CD30, TCRb and TCRc, and the presence of Epstein-Barr virus-encoded small RNA by use of in-situ hybridisation. For straightforward MF or older cases of other CTCLs, available immunohistochemical stains often included only CD3, CD4, CD7, and CD8. In particular, TCRb and TCRc were not available for these cases, being either not necessary for diagnosis, or not available at the time of diagnosis.
T C R d I M M U N O H I S T O C H E M I S T R Y
Immunohistochemical analysis of TCRd was performed with mAb H-41 (SC-100289; Santa Cruz Biotechnology, Santa Cruz, CA, USA). H-41 (1:150; 0.7 lg/ml) was used on an automated stainer platform (Leica Bond-3; Leica, Buffalo Grove, IL, USA) with a heat-based antigen retrieval technique and hipH buffer solution (ER2; Leica), as previously described. 15 TCRd immunohistochemistry was performed for all 144 lesions. On the basis of our prior experience, in which lower percentages of TCRc+ cells that could not be unequivocally correlated with morphologically/immunophenotypically malignant cells, owing to low density and a high mixed cell background, were disregarded in patients with subsequent more diagnostic biopsies of GDTCL, we opted to assess immunostaining for TCRd as a percentage of the total T-cell infiltrate. For the same reasons (suspected intratumoral variability), we accepted any intensity of cytoplasmic and/or membranous staining as positive. Each case received an individual numerical assignment, and was subsequently stratified into one of three categories based on the extent of TCRd+ cells: low, 0-9% (baseline-negative composed of scattered TCRd+ cells); moderate, 10-49%; and high, 50-100%. All non-GDTCL CTCLs with >10% labelling, all GDTCLs with any labelling and all cases of unclear disease type were further analysed for pathological distinctions and detailed clinical information.
Results
C L I N I C A L D A T A
A breakdown of the clinicopathological diagnoses of the 137 patients is shown in Table 1 . Further clinical data on the 40 cases with high and moderate TCRd expression levels are presented below and in Table 2 .
Of CTCL cases with strong and T-cell-specific TCRc expression, 12 of 12 (100%) showed high labelling (50-100%) of TCRd (range 60-95%, mean 85%, median 82%) ( Figure 1A -D).
The percentages of immunohistochemical staining in all CTCL biopsies are shown in Table 1 (15) 2 (2) 2 (2) 16 ( (Figure 2A, D) . One patient was considered clinicopathologically to have SPTCL (occasional subcutaneous nodules localised to the adipose tissue with a CD8 + infiltrate), and is alive 84 months after diagnosis, with responses to different therapies, despite having 70% TCRd+ T cells in this study ( Figure 3L , M). In this patient, immunohistochemistry was performed as a negative control for TCRc validation, and, for the purpose of this study, on TCRd, and the strong positive result was a surprise. Three patients were diagnosed as having epidermotropic T-cell lymphomas with CD4 À /CD8 À diffuse TCRd intraepidermal positivity (80%, 100%, and 100%), but, so far, with an indolent clinical course and an MF-like clinical appearance of patches and plaques (84-month, 24-month and 1-month survival at the time of this study) ( Figure 3A-G) . Of 19 cases with moderate TCRd+ infiltrates, nine (50%) were MF patients, and two each were GDTCL, SPTCL or CD30 + LPD patients (11% each) (Figure 3H-K) . MF patients' infiltrates harboured up to 10-25% cd T cells, and were not diagnostically confusing, whereas the other cases in the moderate category were more difficult.
Four cases from three patients with known GDTCL showed low (two) or moderate (two) labelling. To better understand this unexpected finding, we re-examined the cases. The first case showed only limited patch disease with no TCRc reactivity in the original biopsy, despite later biopsies that showed disease progression to pathological TCRc+ tumours and subsequent death. One patient's biopsy showed only 30% positivity, which, on retrospective review, was the best characterisation of a limited low-tumour-burden lymphoid infiltrate in almost exhausted tissue. Two biopsies from a third patient showed 1% and 30% TCRd labelling, respectively, but the TCRb immunostain on each was difficult to interpret, suggesting that the sample was not adequate for meaningful pathological assessment despite molecular monoclonality. A later biopsy from this patient showed clear-cut GDTCL with 70% TCRd staining, and was positive for TCRc at an outside institution.
T C R d D E L I N E A T E D L Y M P H O M A A N D C L E A R -C U T G D T C L ; S U R V I V A L
Ten of 19 patients (53%) with TCRd+ cells constituting 50-100% of their infiltrates died during followup; all of these were GDTCL patients. Two of them had been thought to have MF with large-cell transformation, but were reclassified upon review of charts and evaluation of immunohistochemical staining patterns as having GDTCL (Figure 4A-H) . No clinicopathologically equivocal patient with TCRd+ cells constituting 50-100% of their infiltrates died during follow-up.
In total, 10 of 15 clear-cut GDTCL patients (67%, 10 of 14 GDTCL patients with high TCRd labelling) died. One patient was lost to follow-up. Seven of the GDTCL patients who died (7/10, 70%) showed both intraepidermal and dermal and/or subcutaneous TCRd+ lymphocytes. One patient had dermal-only localisation of TCRd+ lymphocytes. One patient had an initial intraepidermal TCRdÀ, TCRcÀ, CD4
À and CD8 À presentation, but developed systemic disease with florid visceral TCRd+ tumours. Three GDTCL patients who are currently alive showed mixed intraepidermal and dermal/subcutaneous TCRd+ T cells; one had dermis-limited tumour, and the patient lost to follow-up had a biopsy of fat only (no epidermis present to assess).
Discussion
Cutaneous GDTCL is a distinct aggressive rare cutaneous lymphoma, constituting <1% of all skin lymphomas. It presents with variable clinical features and histological patterns, and its diagnosis is therefore challenging. 3, 6 Because of the lack of a reliable marker of cd T lymphocytes in routine FFPE tissue sections, a presumptive diagnosis used to rely on the absence of TCRab expression as determined with a mAb against TCRb. 6 However, it is known that TCRb expression may be lost by neoplastic ab T cells, so the lack of TCRb cannot and should not be used to confirm a cd origin. 9, 16 Specific antibodies that label c or d chains of the TCRcd heterodimer can allow recognition of cd T cells in skin tissue, and are more specific for GDTCL diagnosis. Routine immunolabelling with a c chain marker in FFPE tissue (clone c3. 20) 3,12,14 had been used successfully for this purpose, but recently became unavailable. Additional challenges with the use of TCRc protein have included the potential for its more promiscuous expression in ab lymphomas, as translation and expression of the TCRc chain may occur in the context of TCRb gene rearrangement, whereas the TCRd gene is deleted in that context, preventing TCRd expression. This suggests that the presence of TCRd expression could be more specific in the diagnosis of GDTCL than in the diagnosis of TCRc. In the current study, we aimed to evaluate the detection and occurrence of cd T cells in CTCLs and CLPDs by using mAb H-41 against TCRd in FFPE tissue, and we found that TCRd expression was comparable to TCRc expression in TCRc+ tumours, with 12 of 12 cases being positive for both TCR chains. All cases that were strongly and diffusely TCRc+ were also TCRd+; we did not identify any TCRc+ cases that were TCRdÀ. TCRc and TCRd appeared to label the same cell populations in the examined biopsies, although some samples were not sequentially assayed (Figure 1) . None of the TCRd+ cases was found to coexpress TCRb. In normal skin, cd T cells are extremely rare, constituting <1% of all CD3 + cells, although up to 30% of intraepidermal T cells, [17] [18] [19] whereas GDTCL is characterised by predominantly TCRd+ T-cell infiltration. 6 All GDTCL patients in our study were TCRd+, with 93% of the patients (14/15) and 80% of their studied biopsies (16/20) showing high labelling of 50-100% of the lymphocytic infiltrate. On retrospective review, outliers were explainable by sampling error. TCRd expression in 30% of the infiltrate was revealed in one patient who went on to have another biopsy 6 years later, showing 80% labelling. Although we considered that this change in expression could represent disease evolution, upon review of the early biopsy the tissue was found to be nearly exhausted at the time of TCRd staining, precluding accurate interpretation. Two cases showed 0% and 1% TCRd expression; however, additional biopsies from each of these showed high TCRd expression; one patient died within a year of florid GDTCL, and the other had a synchronous biopsy showing 70% labelling. This suggested that we had reviewed either early non-diagnostic disease (in the former case), or inadequately sampled or poorly processed tissue (in either case).
As expected, a high mortality rate was found among GDTCL patients in our study (67%, 10/15). Unexpectedly, 70% (7/10) of GDTCL patients who died from disease showed histological involvement of both intraepidermal and dermal and/or subcutaneous skin compartments, versus 60% (3/5) of GDTCL patients who were alive at last follow-up. This pattern of skin involvement in aggressive disease is not in line with previous reports on decreased survival in cases with subcutaneous versus epidermotropic or dermal GDTCL. 4 Our findings align more closely with reports of intraepidermal MF-like GDTCL evolving into aggressive cytotoxic lymphomas after many years of follow-up. 20 We concur that caution is warranted when such patients are followed. It is of note that we did not include CD4 À
/CD8
À , TCRd-high patch/plaque-type T-cell lymphomas in our MF cohort, as we feel that the follow-up on these cases is too limited for meaningful classification. However, the inclusion of such cases within our survival analysis of TCRdhigh infiltrates resulted in improved overall survival as compared with clear-cut clinicopathological GDTCL (67% versus 53%), suggesting that a decision to include such cases as GDTCL needs further study. Numerous cd+ T cells can be found not only in GDTCLs, but also in low-grade CTCLs, CLPDs, 14 and inflammatory self-limited and indolent skin conditions. 10, 17, 20, 21 In our study, 13 cases with typically indolent CTCLs and CLPDs were shown to have lymphocytic infiltrates with 10-25% TCRd positivity, including nine MFs, two SPTCLs, and two CD30 + LPDs. One CD30 + LPD showed TCRd expression in 80-90% of the T-cell infiltrate and negative TCRb labelling. This unusual case presented with indolent, recurrent lesions, and was similar to the recently published six cd T-cell-rich LyP cases that were identified by TCRc+ and/or bF1À immunostaining. 21 Identification of cd T cells by use of TCRd staining in our cases is in support of genuine cd T cells being components of similar infiltrates. In such indolent CTCLs/CLPDs, cd T cells have been reported as constituting up to 20% of lymphocytes. It has been suggested that these cells may represent either a subset of the malignant clone or a reactive T-cell population. 20 Although we did not comparatively assess the intensity of staining within the different compartments of individual patients' infiltrates in this study, we did observe qualitative differences in staining between small peripheral or intraepidermal TCRd+ cells and larger clearly neoplastic cells. Comprehensive characterisation of these subsets may help us to better understand these diseases in the future. For now, given our experience, with 90% of MF cases showing <9% cd T cells, and the remainder showing 10-25%, we suggest closer clinical surveillance and possibly additional biopsies when infiltrates are composed of >25% cd T cells.
Finally, TCRc+ T cells have been described within CD8 + AETCL, and may confound the diagnosis. 22 However, in our study, all five AETCLs were negative for cd T cells by TCRd immunohistochemistry, suggesting that TCRd may have a better negative predictive value for AETCL than TCRc. Larger numbers of AETCLs should be evaluated to better assess this possibility. Overall, our findings highlight the need for cautious evaluation even when low expression of cd (<10%) is identified if the clinical picture is not consonant with the pathological interpretation, given that two of our GDTCL patients who initially had low labelling of TCRd died. Repeated biopsies of multiple sites and lesions in a manner that allows proper evaluation of the relevant tissue depth (sampling the subcutis in panniculitis-like lesions), and consideration of flow cytometric evaluation, are needed to compensate for any possible sampling errors, fixation problems, and disease evolution. In cases of intermediate to high TCRd labelling, in which diagnosis remains unclear, close follow-up is vital and re-biopsy of any change is mandated.
In conclusion, mAb H-14 against TCRd is comparable to TCRc immunohistochemistry and is reliable for the detection of TCRd in malignant and potentially reactive cd T cells in FFPE skin tissue specimens of CTCL/CLPD. Although high numbers of TCRd+ T cells are most often diagnostic for GDTCL, lower numbers of TCRd+ cells can be found in indolent CTCLs and CLPDs. As outliers to these conventions may exist, ensuring adequacy of biopsy and cautious follow-up are essential in all cases with positive TCRd labelling.
